105 related articles for article (PubMed ID: 27175898)
1. Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes.
Piscianz E; Candilera V; Valencic E; Loganes C; Paron G; De Iudicibus S; Decorti G; Tommasini A
Mol Med Rep; 2016 Jul; 14(1):574-82. PubMed ID: 27175898
[TBL] [Abstract][Full Text] [Related]
2. Fate of lymphocytes after withdrawal of tofacitinib treatment.
Piscianz E; Valencic E; Cuzzoni E; De Iudicibus S; De Lorenzo E; Decorti G; Tommasini A
PLoS One; 2014; 9(1):e85463. PubMed ID: 24416411
[TBL] [Abstract][Full Text] [Related]
3. Impact of tofacitinib treatment on human B-cells in vitro and in vivo.
Rizzi M; Lorenzetti R; Fischer K; Staniek J; Janowska I; Troilo A; Strohmeier V; Erlacher M; Kunze M; Bannert B; Kyburz D; Voll RE; Venhoff N; Thiel J
J Autoimmun; 2017 Feb; 77():55-66. PubMed ID: 27793425
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro.
Wang SP; Iwata S; Nakayamada S; Sakata K; Yamaoka K; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2213-5. PubMed ID: 25157177
[No Abstract] [Full Text] [Related]
5. Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro.
Martina MN; Ramirez Bajo MJ; Bañon-Maneus E; Moya Rull D; Hierro-Garcia N; Revuelta I; Campistol JM; Rovira J; Diekmann F
Transplant Proc; 2016 Nov; 48(9):3046-3052. PubMed ID: 27932144
[TBL] [Abstract][Full Text] [Related]
6. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
9. Contributions of mucosal immune cells to methotrexate-induced mucositis.
de Koning BA; van Dieren JM; Lindenbergh-Kortleve DJ; van der Sluis M; Matsumoto T; Yamaguchi K; Einerhand AW; Samsom JN; Pieters R; Nieuwenhuis EE
Int Immunol; 2006 Jun; 18(6):941-9. PubMed ID: 16636014
[TBL] [Abstract][Full Text] [Related]
10. [Tofacitinib for the treatment of rheumatoid arthritis].
Tanaka Y
Nihon Rinsho; 2016 Jun; 74(6):974-80. PubMed ID: 27311188
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Yamaoka K; Tanaka Y
Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
[TBL] [Abstract][Full Text] [Related]
12. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Tanaka Y
J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
14. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
15. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
[TBL] [Abstract][Full Text] [Related]
16. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
17. Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance.
Zhou Y; Leng X; Luo S; Su Z; Luo X; Guo H; Mo C; Zou Q; Liu Y; Wang Y
J Immunol Res; 2016; 2016():5021537. PubMed ID: 28070525
[TBL] [Abstract][Full Text] [Related]
18. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Varisco PA; So A
Rev Med Suisse; 2014 Jan; 10(414):187-91. PubMed ID: 24624736
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?
Fairbanks LD; Rückemann K; Qiu Y; Hawrylowicz CM; Richards DF; Swaminathan R; Kirschbaum B; Simmonds HA
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):143-52. PubMed ID: 10432311
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Tanaka Y; Suzuki M; Nakamura H; Toyoizumi S; Zwillich SH;
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1150-8. PubMed ID: 21584942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
